Pepi (Josefa) Morales is the new Clinical Project Leader at Peptomyc. 

Pepi has a degree in Biological Sciences and a master’s degree in Clinical Biochemistry and Molecular Pathology from Universitat Autònoma de Barcelona (UAB) in Spain and extensive experience in international clinical trials in oncology (phase I to phase III). 

Her wealth of experience includes working at the Spanish Breast Cancer Cooperative Group (SOLTI) for 12 years as Director of Clinical Operations, then 2 years as Technical Director of Clinical Research. During her stay at SOLTI, Pepi led the ClinOps Department, which included more than 20 people involved in the management of phase II and III breast cancer trials, in Neo-/Adjuvant and Metastatic setting. 

In May 2018, she moved to Odonate Therapeutics, Inc. as Director of the Clinical Site Relationship Management for Belgium, Italy, France, Spain and UK. During her stay at Odonate Therapeutics, she was involved in the management of one phase III and two phase II metastatic breast cancer trials, and 2 phase I trials in solid tumors. 

Pepi declares that she is “excited to have the opportunity to be part of this interesting project focused on the development of Omomyc, a new target therapy against cancer. It is a pleasure to be part of this enthusiastic and hardworking Peptomyc Team”. 

Manuela Niewel, Chief Medical Officer of Peptomyc, wishes to “warmly welcome Pepi into the team” and adds that “she will be a fundamental addition into the company with her extremely valuable expertise in Clinical trials”. 

Everybody at Peptomyc is very happy to welcome Pepi to the team! 


Download PDF:
202010 Peptomyc Appoints Pepi Morales as CPM_MN_LS_PM


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 872212